The Effect of Education Given on Preventing Mouth Ulcers in Women With Breast Cancer

NCT ID: NCT07042568

Last Updated: 2025-06-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-13

Study Completion Date

2023-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the effect of nursing education provided to women diagnosed with breast cancer undergoing chemotherapy on their quality of life and the severity of oral mucositis (mouth sores).

The main questions this study aims to answer are:

1. Does nursing education aimed at preventing oral mucositis in women diagnosed with breast cancer have an effect on quality of life?
2. Does nursing education aimed at preventing oral mucositis in women diagnosed with breast cancer have an effect on the severity of oral mucositis? The researchers will evaluate the effect of nursing education on quality of life and oral mucositis severity by randomly assigning one group to receive education and the other group to not receive education.

Participants:

When they come to receive their chemotherapy treatment (on the first day of the evaluation), the researcher will fill out a scale measuring quality of life and scales checking the condition of the oral mucosa. Participants in the education group will receive education from the researchers using an education booklet prepared by the researchers, and the booklet will remain with the participants. On days 7 and 14, the researcher will provide telephone consultation. On the 21st day, when the final evaluation will be conducted, data will be collected from participants through the scales.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a two-armed, single-blind, randomised controlled trial (RCT). Participants were selected from an oncology hospital affiliated with a university hospital in western Turkey between February and August 2023. Women who met the following criteria were included in the study: Women diagnosed with breast cancer who were undergoing chemotherapy, aged 18 years or older, voluntarily participating in the study, capable of communicating in Turkish, and able to read and write, with at least three weeks of chemotherapy treatment remaining.

Patients who met the following criteria were excluded from the study: having a known psychiatric disorder that could interfere with the intervention and data collection process, receiving chemoradiotherapy, or having cognitive, perceptual, or communication problems that could affect their ability to understand the training provided.

To determine the sample size, a pre-power analysis was performed using the G-Power 3.1.9.7 programme. For this analysis, the initial measurement total mean EORTC QLQ-C30 quality of life scale scores of the intervention and control groups in the study by Yüce and Yurtsever \[24\] were used. According to the analysis results, with an effect size of 0.65, a significance level of p\<0.05 in each group, a 95% confidence interval, and 80% test power, a minimum of 78 participants (39 participants each for the intervention and control groups) was determined. A total of 91 patients were reached during the specified dates, but 6 patients did not wish to continue the study and were therefore not included in the analysis. The study was completed with a total of 85 participants, including 43 in the intervention group and 42 in the control group.

After obtaining the necessary ethical committee and institutional approvals for this study, it was conducted through face-to-face interviews in a suitable room in the outpatient chemotherapy unit on the first day and the 21st day of chemotherapy for female patients diagnosed with breast cancer who met the inclusion criteria. On the first day of the interview, all participants were informed about the purpose and method of the study, and it was emphasised that participation in the study was entirely voluntary. Written informed consent was obtained through an informed consent form.

Taking into account the order of the randomisation table, one participant was included in the study each day, and on the first day of the interview, the researchers administered the Patient Information Form, the World Health Organisation (WHO) Oral Toxicity Criteria, the Oral Assessment Guide (OAG), European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30) Version 3.0 Quality of Life Scale, Eastern Cooperative Oncology Group (ECOG) Performance Scale. In addition, the intervention group was trained on the use of the Oral Mucositis Prevention Patient Education Handbook, which was prepared by the researchers based on literature information and expert opinions. Participants in the intervention group received telephone consultations on days 7 and 14. The control group continued to receive routine nursing care. The second interview was completed on day 21, when both the intervention and control group patients returned for their next treatment cycle, using the WHO Oral Toxicity Criteria, ADR, and EORTC QLQ-C30 Version 3.0 Quality of Life Scale.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Early Stage Breast Cancer (Stage 1-3) Chemotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention (Education + Telephone consultation)

Group Type EXPERIMENTAL

Nursing education aimed at preventing oral mucositis

Intervention Type BEHAVIORAL

The intervention group was trained on the use of the Oral Mucositis Prevention Patient Education Handbook, which was prepared by the researchers based on literature information and expert opinions. Participants in the intervention group received telephone consultations on days 7 and 14. The control group continued to receive routine nursing care. The second interview was completed on day 21, when both the intervention and control group patients returned for their next treatment cycle, using the WHO Oral Toxicity Criteria, ADR, and EORTC QLQ-C30 Version 3.0 Quality of Life Scale.

Control group

They continued to receive routine nursing care.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nursing education aimed at preventing oral mucositis

The intervention group was trained on the use of the Oral Mucositis Prevention Patient Education Handbook, which was prepared by the researchers based on literature information and expert opinions. Participants in the intervention group received telephone consultations on days 7 and 14. The control group continued to receive routine nursing care. The second interview was completed on day 21, when both the intervention and control group patients returned for their next treatment cycle, using the WHO Oral Toxicity Criteria, ADR, and EORTC QLQ-C30 Version 3.0 Quality of Life Scale.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women diagnosed with breast cancer and undergoing chemotherapy,
* Aged 18 or older,
* Volunteering to participate in the study,
* Able to communicate, read and write in Turkish,
* With at least 3 weeks of chemotherapy treatment remaining

Exclusion Criteria

* Having a known psychiatric illness that could interfere with the intervention and data collection process,
* Receiving chemo-radiotherapy,
* Having cognitive, perceptual, or communication issues that may affect their ability to understand the provided education.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Trakya University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

YAREN ÖZBEK

Research Assistant

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Balkan Oncology Hospital affiliated with Trakya University Hospital, Trakya University, Republic of Turkey

Edirne, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TÜTF-GOBAEK 2022/382

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.